Familial hypercholesterolaemia (FH) is an autosomal dominant condition, marked by elevated plasma concentrations of low-density lipoprotein (LDL)-cholesterol from birth. It confers a substantial risk of premature atherosclerotic cardiovascular disease (ASCVD), posing a major public health burden due to potential lifelong exposure to high LDL-cholesterol concentrations if untreated [1]. Despite growing awareness, FH continues to be underdetected and untreated, particularly in community settings, because of lack in implementation of evidence informed care, sparking several international calls to action [1].
